Company 2, Student Brigade, Daping Hospital, Third Military Medical University, Chongqing, China.
J Diabetes. 2012 Mar;4(1):22-9. doi: 10.1111/j.1753-0407.2011.00167.x.
The prevalence of type 2 diabetes mellitus (T2DM) has increased markedly worldwide. A recent epidemiological study reported that approximately 63% of T2DM patients also have high blood pressure (>130/80 mmHg), which doubles their risk of cardiac events. Of the medications used to treat T2DM, the incretins are a group of peptides that not only regulate blood glucose effectively and moderately, but also protect patients against cardiovascular events and improve several cardiovascular parameters. Here were review data from preclinical and short- and long-term clinical studies investigating the antihypertensive effects of incretins. We also elucidate four possible mechanisms underlying the antihypertensive effects of incretins. We conclude that incretins can lower blood pressure of T2DM patients, independent of weight loss, and will surely improve the prognosis of these patients.
2 型糖尿病（T2DM）的患病率在全球范围内显著增加。最近的一项流行病学研究报告称，约 63%的 T2DM 患者也患有高血压（>130/80mmHg），这使他们发生心脏事件的风险增加了一倍。在用于治疗 T2DM 的药物中，肠促胰岛素是一组肽类物质，它们不仅能有效且适度地调节血糖，还能保护患者免受心血管事件的影响，并改善多项心血管参数。本文综述了来自临床前和短期及长期临床试验的数据，这些研究调查了肠促胰岛素的降压作用。我们还阐明了肠促胰岛素降压作用的四个可能机制。我们的结论是，肠促胰岛素可以降低 T2DM 患者的血压，而与体重减轻无关，肯定会改善这些患者的预后。
